Masimo (MASI) Scheduled to Post Quarterly Earnings on Tuesday

Masimo (NASDAQ:MASI) is set to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Masimo to post earnings of $0.71 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, beating the consensus estimate of $0.82 by $0.43. The firm had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business’s quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.32 earnings per share. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Trading Up 0.6 %

Shares of NASDAQ MASI opened at $137.00 on Monday. Masimo has a twelve month low of $75.22 and a twelve month high of $188.76. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The stock has a market cap of $7.25 billion, a price-to-earnings ratio of 90.73 and a beta of 0.99. The company’s fifty day moving average is $136.10 and its 200-day moving average is $118.80.

Insider Buying and Selling at Masimo

In related news, Director Craig B. Reynolds sold 40,000 shares of Masimo stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the completion of the sale, the director now owns 7,406 shares of the company’s stock, valued at approximately $1,008,475.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the topic of a number of research analyst reports. Jefferies Financial Group restated a “hold” rating and set a $121.00 price objective (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and increased their price target for the company from $148.00 to $170.00 in a research report on Monday, April 15th. Wells Fargo & Company raised Masimo from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. StockNews.com raised Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Finally, BTIG Research boosted their target price on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus price target of $137.43.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.